Vertex Pharmaceuticals
VRTX
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Business Wire • 4 days ago • VRTX
Jennifer Schneider Elected to Vertex Board of DirectorsForbes • 5 days ago • VRTX
Vertex Is Writing A New Playbook For Pharma R&D. And It's Working.Zacks Investment Research • 5 days ago • VRTX
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth StockInvestorPlace • 5 days ago • VRTX
3 Cheap Biotech Stocks to Buy Now: May 2024The Motley Fool • 6 days ago • VRTX
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart BuyCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.